HC Wainwright restated their buy rating on shares of Pliant Therapeutics (NASDAQ:PLRX – Get Rating) in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a $54.00 target price on the stock. Several other analysts have also issued reports on PLRX. Royal Bank of Canada dropped their target price on […]